NovaGenix Insights

FDA Removes Tirzepatide (Mounjaro, Zepbound) from Drug Shortage List: What It Means for Patients Using Compounded Versions and Reasons Behind There Sudden Reversal Tirzepatide No Longer in Short Supply: Impact on Compounded Medications for Weight Loss Tirzepatide No Longer in Short Supply: Impact on Compounded Medications for Weight Loss As of October 2024, the FDA has officially removed tirzepatide   (the active ingredient in Mounjaro and Zepbound) from its drug shortage list. This change follows months of high demand for tirzepatide, which is used for both diabetes and weight-loss treatments. Due to the rising popularity of GLP-1 medications for weight loss , many patients experienced difficulties obtaining them. Eli Lilly, the manufacturer, increased production capacity, restoring full availability in pharmacies. Lilly's drugs   have recently taken the world of weight loss by storm, however, this has impacted providers and patients who relied on affordable, effective comp...

Which Medication is Better for Weightloss? Wegovy or Mounjaro? Understanding the Contrasts: Semaglutide vs. Tirzepatide for Weight Management. Obesity and the need for effective weight loss treatments . The need for clinical solutions to a growing problem in the U.S. The escalating prevalence of obesity has become a major global health challenge, affecting millions of individuals worldwide. Contributing factors include sedentary lifestyles, unhealthy eating habits, and societal changes, creating an epidemic with far-reaching implications. Beyond the physical health impact, obesity takes a toll on mental well-being and strains healthcare systems. Given its association with serious conditions like diabetes and heart disease, there is an urgent need for effective weight loss treatments. Traditional interventions have often proven inadequate, prompting a quest for innovative solutions. Semaglutide and tirzepatide, marketed as   Ozempic ,  Wegovy ,  Mounjaro  an...